Sorafenib is the first oral medicine approved for the treatment of advanced liver cancer and inhibits the growth of tumour cells and angiogenesis by suppressing the activation of a variety of silk/threonine kinases and tyrosine kinases (such as B-Raf and vascular endothelial growth factor receptor)25–27. Here, BRAF is linked to neoplasm.